Arsenal Medical said today it won a contract from the U.S. Army Medical Research & Materiel Command worth more than $14 million to complete clinical and manufacturing development and regulatory submission for its ResQFoam. Arsenal’s ResQFoam is a self-expanding biomaterial designed to be administered at the point of injury to stop blood loss in patients […]
Medtronic (NYSE:MDT) this week said it took out a stake with an exclusive option to buy in Arsenal Medical subsidiary Arsenal AAA. Arsenal AAA is developing a hemostatic foam and delivery system designed to reduce the chance of endoleaks after the placement of a stent graft to treat an abdominal aortic aneurysm. Arsenal president & CEO Maria Palasis told MassDevice.com that the product is designed […]
Medtronic (NYSE:MDT) yesterday said it took out a stake with an option to buy on Arsenal Medical subsidiary Aresenal AAA and its hemostatic foam.* Arsenal AAA is developing the foam and a delivery system that are designed to reduce the chance of endoleaks after the placement of a stent graft to treat an abdominal aortic aneurysm. Financial terms […]
Sister companies Arsenal Medical and 480 Biomedical said yesterday that they raised $26.5 million in joint funding to advance their respective product platforms. Arsenal raised $16 million and 480 Biomedical $10.5 million from Polaris Partners, North Bridge Venture Partners and Intersouth Partners, the companies said; 480 Biomedical’s round also included a long-term strategic investor. Conversions […]
On July 15, 2014, MassDevice.com brought together 4 senior medtech leaders to discuss the future of the medical device industry at our DeviceTalks Boston event.
Arsenal Medical, a company that makes internal-bleeding control products for battlefield situations, brought in $4 million from 8 un-named investors in a funding round that opened last month.
Watertown, Mass.-based Arsenal Medical received a $15.5 million Phase II contract from the Defense Advanced Research Projects Agency to support its wound management product.
The foam-based product could help combat medics control hemorrhaging in the intact abdominal cavity and reduce battlefield mortality, a large percentage of which is caused by internal bleeding from abdominal injuries, according to a press release.
Cleveland HeartLab pulled in $14.7 million in equity financing for its proprietary test for cardiac inflammation, according to a regulatory filing.
The CardioMPO test was developed by Dr. Stanley Hazen, director of the Cleveland Clinic’s center for cardiovascular diagnostics and prevention.
Cleveland HeartLab closed a $3 million round in 2010, with backers including Glengary and Second Generation Ltd.
Partners Healthcare’s Center won a research grant to pilot a text messaging program aimed at helping diabetic patients manage their condition.
The grant, provided by McKesson, was awarded to the hospital system’s Center for Connected Health.
The program, called Mobilizing for Health, targets under-served patients to study whether personalized text messages have an impact on clinical outcomes and physical activity in people with Type II diabetes, who are often obese and have low activity levels.